Abstract | OBJECTIVES: METHODS: Patients (N = 121) were treated with ER niacin/ laropiprant 1 g/20 mg for 4 weeks and then the dose was doubled for an additional 8 weeks. Measurements of fasting lipids, glucose, insulin, and adiponectin were performed at baseline and during the study. RESULTS: There were significant (P < 0.001) increases in glucose (9.4 ± 13.1%), insulin (70.2 ± 91.0%), HOMA-IR (87.8 ± 103.9%), and adiponectin (169.3 ± 111.6%). The increase in adiponectin was significantly associated with increase in glucose (r = 0.221, P < 0.05), insulin (r = 0.184, P < 0.05), and HOMA-IR (r = 0.237, P < 0.01) and the association remained significant after adjustment for changes in body weight or body fat mass. CONCLUSION:
|
Authors | Miao Hu, Ya-Ling Yang, Daisaku Masuda, Shizuya Yamashita, Brian Tomlinson |
Journal | Disease markers
(Dis Markers)
Vol. 2015
Pg. 154014
( 2015)
ISSN: 1875-8630 [Electronic] United States |
PMID | 26063948
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adiponectin
- Blood Glucose
- Hypolipidemic Agents
- Indoles
- Insulin
- MK-0524
- Vitamin B Complex
- Niacin
|
Topics |
- Adiponectin
(blood)
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Blood Glucose
(metabolism)
- China
- Dyslipidemias
(blood, drug therapy)
- Female
- Humans
- Hypolipidemic Agents
(therapeutic use)
- Indoles
(therapeutic use)
- Insulin
(blood)
- Insulin Resistance
- Male
- Middle Aged
- Niacin
(therapeutic use)
- Vitamin B Complex
(pharmacology)
|